Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities

Modern Pathology

Volumn 25, Issue 1, 2012, Pages 65-74

  Boiocchi, Leonardo ^a,b   Orazi, Attilio ^a   Ghanima, Waleed ^a,c   Arabadjief, Melissa ^a   Bussel, James B ^a   Geyer, Julia Turbiner ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c Østfold Hospital Trust   (Norway)

Author keywords

bone marrow biopsy; c MPL; megakaryocyte; myeloproliferative marrow; primary immune thrombocytopenia; thrombopoietin receptor agonists

Indexed keywords

COLLAGEN; HEMOSTATIC AGENT; RETICULIN; THROMBOPOIETIN RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; BONE MARROW BIOPSY; BONE MARROW DISEASE; BONE MARROW HYPERCELLULARITY; CHILD; DISEASE ASSOCIATION; DISEASE SEVERITY; FOLLOW UP; HEMATOPOIESIS; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MEGAKARYOCYTE; MYELOFIBROSIS; PRESCHOOL CHILD; PRIMARY IMMUNE THROMBOCYTOPENIA; PRIORITY JOURNAL; RETICULIN FIBROSIS; SCHOOL CHILD; STROMA CELL;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; BIOPSY; BONE MARROW CELLS; BONE MARROW EXAMINATION; CHILD, PRESCHOOL; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGIC FACTORS; MALE; MEGAKARYOCYTES; MIDDLE AGED; PRIMARY MYELOFIBROSIS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, THROMBOPOIETIN; RETICULIN; STROMAL CELLS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84855345560     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.128     Document Type: Article

References (41)

1. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386-2393.
2. Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 2005;106:2244-2251. (Pubitemid 41510792)
3. Bussel JB. Traditional and new approaches to the management of immune thrombocytopenia: issues of when and who to treat. Hematol Oncol Clin North Am 2009;23:1329-1341.
4. Hasan A, Michel M, Patel V, et al. Repeated courses of rituximab in chronic ITP: three different regimens. Am J Hematol 2009;84:661-665.
5. Aleem A, Alaskar AS, Algahtani F, et al. Rituximab in immune thrombocytopenia: transient responses, low rate of sustained remissions and poor response to further therapy in refractory patients. Int J Hematol 2010;92:283-288.
6. Wang J, Wiley JM, Luddy R, et al. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr 2005;146:217-221. (Pubitemid 40202812)
7. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis- stimulating protein, for chronic ITP. N Engl J Med 2006;355:1672-1681. (Pubitemid 44583957)
8. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357:2237-2247. (Pubitemid 350190754)
9. Sattler M, Durstin MA, Frank DA, et al. The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. Exp Hematol 1995;23:1040-1048.
10. Rojnuckarin P, Drachman JG, Kaushansky K. Thrombopoietin-induced activation of the mitogen-activated protein kinase (MAPK) pathway in normal megakaryocytes: role in endomitosis. Blood 1999;94: 1273-1282. (Pubitemid 29380408)
11. Miyakawa Y, Rojnuckarin P, Habib T, et al. Thrombopoietin induces phosphoinositol 3-kinase activation through SHP2, Gab, and insulin receptor substrate proteins in BAF3 cells and primary murine megakaryocytes. J Biol Chem 2001;276:2494-2502.
12. Bussel JB, Kuter DJ, Pullarkat V, et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009;113:2161-2171.
13. Kuter DJ, Mufti GJ, Bain BJ, et al. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood 2009;114:3748-3756.
14. Chiu A, Nanaji NM, Czader M, et al. The stromal composition of mast cell aggregates in systemic mastocytosis. Mod Pathol 2009;22:857-865.
15. Thiele J, Kvasnicka HM, Diehl V. Standardization of bone marrow features-does it work in hematopathology for histological discrimination of different disease patterns? Histol Histopathol 2005;20:633-644. (Pubitemid 40468281)
16. Douglas VK, Tallman MS, Cripe LD, et al. Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders. Am J Clin Pathol 2002;117:844-850. (Pubitemid 34564339)
17. Gianelli U, Iurlo A, Vener C, et al. The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the 'early' prepolycythemic phase of polycythemia vera and essential thrombocythemia. Am J Clin Pathol 2008;130:336-342.
18. Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005;90:1128-1132. (Pubitemid 41323513)
19. Yan XQ, Lacey D, Hill D, et al. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation. Blood 1996;88:402-409. (Pubitemid 26240370)
20. Villeval JL, Cohen-Solal K, Tulliez M, et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood 1997;90:4369-4383. (Pubitemid 27508443)
21. Frey BM, Rafii S, Teterson M, et al. Adenovectormediated expression of human thrombopoietin cDNA in immune-compromised mice: insights into the pathophysiology of osteomyelofibrosis. J Immunol 1998;160:691-699. (Pubitemid 28049309)
22. Yan XQ, Lacey D, Fletcher F, et al. Chronic exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice. Blood 1995;86:4025-4033.
23. Beckman EN, Brown Jr AW. Normal reticulin level in iliac bone marrow. Arch Pathol Lab Med 1990;114: 1241-1243.
24. Bauermeister DE. Quantitation of bone marrow reticulin-a normal range. Am J Clin Pathol 1971;56: 24-31.
25. Ettrup MS, Jensen AO, Engebjerg MC, et al. Bone marrow reticulin and collagen content in patients with adult chronic immune thrombocytopenic purpura: A Danish nationwide study. Am J Hematol 2010; 85:930-934.
26. Kuter DJ, Bain B, Mufti G, et al. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol 2007;139: 351-362. (Pubitemid 47512180)
27. Chagraoui H, Komura E, Tulliez M, et al. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood 2002;100:3495-3503. (Pubitemid 35303916)
28. Ciurea SO, Merchant D, Mahmud N, et al. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood 2007;110: 986-993. (Pubitemid 47267438)
29. Thiele J, Rompcik V, Wagner S, et al. Vascular architecture and collagen type IV in primary myelofibrosis and polycythaemia vera: an immunomorphometric study on trephine biopsies of the bone marrow. Br J Haematol 1992;80:227-234.
30. Lisse I, Hasselbalch H, Junker P. Bone marrow stroma in idiopathic myelofibrosis and other haematological diseases. An immunohistochemical study. APMIS 1991;99:171-178.
31. Caneva L, Soligo D, Cattoretti G, et al. Immunoelectron microscopy characterization of human bone marrow stromal cells with anti-NGFR antibodies. Blood Cells Mol Dis 1995;21:73-85.
32. Levine RL, Pardanani A, Tefferi A, et al. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007;7:673-683. (Pubitemid 47327415)
33. Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994;369:568-571. (Pubitemid 24192526)
34. Alexander WS, Roberts AW, Nicola NA, et al. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood 1996;87:2162-2170.
35. Sitnicka E, Lin N, Priestley GV, et al. The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells. Blood 1996;87: 4998-5005. (Pubitemid 26189841)
36. Nishino T, Miyaji K, Ishiwata N, et al. Ex vivo expansion of human hematopoietic stem cells by a small-molecule agonist of c-MPL. Exp Hematol 2009;37:1364-1377 e4.
37. Qian H, Buza-Vidas N, Hyland CD, et al. Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. Cell Stem Cell 2007;1:671-684. (Pubitemid 350215331)
38. Kaushansky K. Thrombopoietin: accumulating evidence for an important biological effect on the hematopoietic stem cell. Ann NY Acad Sci 2003;996:39-43. (Pubitemid 36706584)
39. Yamazaki S, Nakauchi H. Insights into signaling and function of hematopoietic stem cells at the single-cell level. Curr Opin Hematol 2009;16:255-258.
40. Yoshihara H, Arai F, Hosokawa K, et al. Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell 2007;1:685-697. (Pubitemid 350215333)
41. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-397. (Pubitemid 40544655)